


# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

Date: 11<sup>th</sup> August 2016

To,

Listing Department,  
Bombay Stock Exchange,  
Dalal Street Fort,  
Mumbai - 400001

Subject: Unaudited financial results for the Quarter ended 30<sup>th</sup> June 2016

Dear Sir,

Enclosed herewith a copy of the Un-audited Financial Results of the Company for the Quarter ended 30<sup>th</sup> June 2016 duly approved by the Board of Directors of the Company at their meeting held on 11<sup>th</sup> August 2016 along with the Limited Review Report as issued by the Statutory Auditor of the Company.

Thanking you

Yours Faithfully  
For FREDUN PHARMACEUTICALS LIMITED

DIRECTOR

Enclosed as above

# Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W) MUMBAI - 400 031.

PHONE : 24102526, 24112526

FAX : 24132121

## LIMITED REVIEW REPORT


**TO THE BOARD OF DIRECTORS OF  
FREDUN PHARMACEUTICALS LTD**  
26, Manoj Industries Premises,  
G.P. Ambekar marg, Wadala,  
Mumbai - 400 031.

1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended June 30, 2016 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MUMBAI, August 11, 2016

FOR SAVLA & ASSOCIATES  
Chartered Accountants  
(Firm Registration No.109361W)

  
DEEPAK G. SAVLA  
(Partner)

Membership No. : 043901

# FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

FREDUN PHARMACEUTICALS LTD.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THREE MONTHS ENDED

30 Jun 16

Rs. in Lacs

NO	PARTICULARS	Quarter ended			Year ended
		30.06.2016 (Unaudited)	31.03.2016 (Audited)	30.06.2015 (Unaudited)	31.03.2016 (Audited)
1	<b>Income from Operations</b>				
	a) Net Sales /IncomeFrom Operation (Net of Excise Duty)	1649.90	1582.68	791.60	4232.13
	b) Other Operating Income	17.57	16.76	12.73	86.18
	Total income from operations (net)	1667.47	1599.44	804.33	4318.31
2	<b>Expenses</b>				
	a) Cost of Material Consumed	809.22	1111.06	578.41	3042.33
	b) Purchases of stock -in-trade	0.00	7.77	0.00	82.84
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	426.58	(177.20)	(71.21)	(442.05)
	d) Employess benefits expenses	99.57	127.62	89.69	382.56
	e) Depreciation and amortisation expenses	20.11	39.45	13.65	80.43
	f) Other Expenses	198.37	294.94	125.11	776.02
	Total Expenditure	1553.85	1403.64	735.65	3922.13
	Profit/(Loss) from operations before other income, finance costs and exceptional item (1-2)	113.62	195.80	68.68	396.18
3	Other income	0.00	0.00	0.00	0.00
4	item (3+4)	113.62	195.80	68.68	396.18
5	Less : Finance Cost	37.90	83.60	36.18	205.93
6	exceptional item (5-6)	75.72	112.20	38.50	190.25
7	Exceptional items	0.00	(6.75)	0.00	(6.75)
8	Profit/(Loss) from ordinary activities before tax (7-8)	75.72	105.45	38.50	183.50
9	Tax Expenses	15.00	66.55	0.00	76.55
10	Net Profit/(Loss) from ordinary activities after tax (9-10)	60.72	38.90	38.50	106.95
11	Extraordinary item (net of tax expenses)	0.00	0.00	0.00	0.00
12	Net Profit/(Loss) for the period (11-12)	60.72	38.90	38.50	106.95
13	Paid up Equity Share Capital (Face Value of Rs-10/- each)	237.45	237.45	237.45	237.45
14	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	133.53
15	Earning per Share (EPS) (before & after extra ordinary items)	2.56	1.64	1.62	4.55
	- Basic/ Diluted Earning Per Share (Rs.)	2.56	1.64	1.62	4.55
A	1) Public Shareholding				
	Number of shares	601290	601290	601290	601290
	Percentage of shareholding	25.56	25.56	25.56	25.56
	2) Promoters and promotor group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of total shareholding of Promoters and Prompte	-	-	-	-
	- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-
	b) Non-encumbered				
	- Number of shares	1751110	1751110	1751110	1751110
	- Percentage of shares (as a % of total shareholding of Promoters and Prompte	100%	100%	100%	100%
	- Percentage of shares (as a % of total share capital of the Company)	74.44	74.44	74.44	74.44

NOTES:-

- 1) The above results were taken on record by the Board Of Directors at the meeting held on 11.08.2016
- 2) Previous year's figures have been regrouped/rearranged wherever necessary.
- 3) During the quarter ended 30th June 2016 there are no investor's complaints pending & no investor's complaints were received by the company during this period.
- 4) Provision for deferred tax as per Accounting Standard 22 of the institute of Chartered Accountants of India as applicable will be made at the end of the year.
- 5) Dividend on Preference shares will be considered at the year end.
- 6) The above result have already been approve by the Audit Committee of the board

PLACE: MUMBAI

DATE : 11.08.2016



FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR

Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA)

Phone : 91-22 – 4031 8111 Fax : 91-22-40318133 E-mail : business@fredungroup.com Web : www.fredungroup.com